[ad_1] Article content INGELHEIM, Germany & BASEL, Switzerland — Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an…
Tag: ImmunoOncology
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies
[ad_1] Potential acquisition of VyGen-Bio would strengthen Coeptis’ oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies WEXFORD, Pa., March 29, 2023 /PRNewswire/ —…